Few topics in women's health carry more confusion, fear, and outdated information than hormone replacement therapy. Women are told to avoid it. Women are told it causes cancer. Women are told the risks are too high — and then sent home to manage years of symptoms with nothing.
Most of that messaging is rooted in a 2002 study that the medical community has spent two decades walking back. And in the meantime, a generation of women suffered unnecessarily.
Here's what the evidence actually shows.
Where the Fear Came From
In 2002, the Women's Health Initiative (WHI) published interim results from a large randomized controlled trial of hormone therapy. The initial headlines were alarming: increased risks of breast cancer, heart disease, stroke, and blood clots. Physicians rapidly stopped prescribing hormones. Women stopped taking them. The practice of hormone therapy contracted dramatically.
But the full picture was more complicated than the headlines — and the decades of research that followed have substantially revised our understanding.
The WHI studied a specific population: women with an average age of 63, many of whom were more than ten years past menopause, and many of whom had cardiovascular risk factors at baseline. The primary formulation studied was oral conjugated equine estrogen combined with medroxyprogesterone acetate — synthetic progestin — taken orally.
That formulation, that population, and that route of administration are not representative of how hormone therapy is commonly prescribed today, or of the women most likely to benefit from it.
What We Know Now
The medical evidence on hormone therapy has evolved considerably. Here's where the major professional societies — including the Menopause Society (formerly NAMS), the British Menopause Society, and others — currently stand:
For most healthy women under 60, or within ten years of menopause onset, the benefits of hormone therapy outweigh the risks. This is sometimes called the "timing hypothesis" or the "window of opportunity" — the concept that initiating hormone therapy early in the menopause transition, when the cardiovascular and neurological systems are still relatively healthy, has a meaningfully different risk-benefit profile than initiating it years later.
Transdermal estrogen carries a lower clot risk than oral estrogen. When estrogen is absorbed through the skin (patch, gel, or spray) rather than taken by mouth, it bypasses first-pass liver metabolism. The result is a clot risk profile that is not meaningfully elevated above baseline — a significant distinction from the oral formulations that drove much of the WHI's cardiovascular findings.
The type of progestogen matters. Not all progestogens are equivalent. Micronized bioidentical progesterone (such as Prometrium) has a more favorable safety profile than synthetic progestins like medroxyprogesterone acetate, particularly with respect to breast cancer risk and cardiovascular effects. The choice of progestogen is a clinically meaningful one.
The breast cancer question is nuanced. Estrogen alone (used in women who have had a hysterectomy) does not appear to increase breast cancer risk and may actually modestly reduce it. The signal for combined estrogen-progestogen therapy and breast cancer risk is real but small in absolute terms — comparable in magnitude to the risk associated with having one additional alcoholic drink per day or with obesity — and varies by the type of progestogen used. Context matters: the absolute risk increase for most women is small, and this risk must be weighed against the significant benefits of treatment.
There are substantial long-term benefits beyond symptom relief. Hormone therapy has well-documented protective effects on bone density, reducing fracture risk. Emerging evidence supports cardiovascular benefit when initiated early in the transition. There is active research on the role of estrogen in cognitive health and dementia risk — not yet definitive, but promising and clinically relevant.
What "Bioidentical" Actually Means
The term "bioidentical" has been heavily marketed — often in ways that conflate FDA-approved bioidentical hormones with compounded preparations, implying that custom-compounded hormones are safer or more natural. This distinction matters.
FDA-approved bioidentical hormones — including estradiol patches, gels, and sprays, and micronized progesterone — are bioidentical (molecularly identical to the hormones your body produces), well-studied, and tightly regulated for purity and consistency.
Compounded bioidentical hormones — including pellets and custom-formulated creams — are not FDA-approved, have variable absorption and dosing, and lack the safety data that FDA-approved preparations have. Salivary hormone testing, often promoted alongside compounded preparations, is not a validated or reliable measure of tissue hormone levels.
Evidence-based hormone therapy means using well-studied formulations with known absorption characteristics and demonstrated safety profiles. That's the standard I practice to.
Who Is a Candidate?
Hormone therapy is appropriate for most healthy women who:
- Are experiencing significant vasomotor symptoms (hot flashes, night sweats)
- Are in perimenopause or within ten years of their final menstrual period
- Are without significant cardiovascular disease, active hormone-sensitive cancer, unexplained vaginal bleeding, or active clotting disorder
Women with a history of breast cancer, cardiovascular disease, or other complex medical histories require individualized evaluation — not automatic exclusion. Many women with these histories can still benefit from carefully considered hormonal or non-hormonal treatment, in collaboration with their full care team.
Women who are not candidates for systemic hormone therapy, or who prefer not to use it, have real evidence-based options: local vaginal estrogen for genitourinary symptoms, fezolinetant for vasomotor symptoms, and selected non-hormonal medications with clinical evidence behind them.
Why This Requires a Specialist Conversation
Hormone therapy is not a simple decision — but it's also not the minefield of risk that it was portrayed as in 2002. Making a good decision requires:
- A complete medical history and risk assessment
- An honest conversation about what the evidence actually shows, for your specific situation
- A clinician who is up to date on the current literature — not still practicing based on 2002 headlines
- Time to answer your questions without feeling rushed
That's the conversation I have with every patient at Metis Midlife Medicine. Not a protocol. Not a script. A real discussion about your health, your history, your symptoms, and what the evidence supports for you specifically.
The Bottom Line
Hormone therapy, when prescribed thoughtfully and with appropriate formulations, is safe and effective for the majority of women in the menopause transition. The fear that has kept millions of women from accessing effective treatment is not well-supported by the current evidence.
You deserve accurate information — and the chance to make a real, informed decision about your own care.
If you're in Colorado or Texas and want to have this conversation with a menopause medicine specialist, I'd welcome the opportunity. Reach out to schedule a consultation with Metis Midlife Medicine.
Metis Midlife Medicine is a telemedicine practice serving patients in Colorado and Texas. Dr. Sapp is board-certified in Family Medicine and Obesity Medicine and holds the Menopause Society Certified Practitioner (MSCP) designation. This article is for educational purposes only and is not a substitute for individualized medical advice.